SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should ...

Even though CoVs can rapidly evolve to gain resistance to the conventional small molecule drugs, peptide-based inhibitors targeting various steps of CoV lifecycle remain a promising approach. Peptides ...

To sum up, SARS-CoV-2 infection mediated by ACE2 is a multimolecular interaction process, and the complexity of this process means that inhibitors developed for a single target do not necessarily have ...

Current approaches for studying SARS-CoV-2 fusion include computational studies, pan-coronavirus viral inhibitors, and modified peptides and lipopeptides ... Additionally, this study modifies the LION ...

SARS-CoV-2 enters host cells via cell receptor ACE II (ACE2) and the transmembrane serine protease 2 (TMPRSS2). In order to identify possible prime target cells of SARS-CoV-2 by comprehensive ...

2025 年 2 月 18 日，广州实验室石正丽、彭伟、周鹏、武汉大学严欢、广东省科学院动物研究所张礼标等人在国际顶尖学术期刊 Cell 上发表了题为：Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor 的研究论文。 该研究从蝙蝠中发现了一种独特的 ...

Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg12O12 and Zn12O12 nanoclusters: an in silico strategy for COVID-19 treatment.

The study explores the potential of chitosan derivatives as novel inhibitors against the wild-type and emerging variants of ...

Protein Stable Ltd., 21 Mole Business Park, Leatherhead KT22 7BA, U.K.